The oral semaglutide results were slightly better than what appeared in the PIONEER trials (1.8% average reduction versus 1.1%), while the injectable results were comparable to the SUSTAIN trials (1.4% versus 1.56%).[1] The weight loss results from this real-world study were somewhat better than clinical trials, which researchers attribute to the higher baseline weight in their patient population (average 106.9 kg versus 88-92 kg in trials) and concurrent use of other medications that contribute to weight loss.[1] Study Strengths and Limitations The study's main strength is that it reflects actual clinical practice
He constantly hears patients tell him, I dont want to use a shortcut, when discussing anti-obesity medications
Its not clear whether probiotics will help very much, at least for prevention of C
Antioxidant Protection: Helps neutralise free radicals, protecting cells from oxidative damage
According to Beckers Hospital Review, some insurers and self-funded employers across America are dropping coverage altogether or imposing strict limits in 2025, reflecting the financial and operational challenges posed by the high-cost medications